Karyopharm Therapeutics Inc.
KPTI
Positions held
Your positionsKPTI isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $13.61M | Enterprise value | $277.03M | Trailing P/E | — | Forward P/E | -0.21 |
| PEG | — | Price / book | -0.04 | Beta | 1.04 | Dividend yield | 0.00% |
| Revenue growth | -11.9% | Earnings growth | — | Gross margin | 99.1% | Operating margin | -67.4% |
| Profit margin | -1.5% | ROE | — | ROA | -47.6% | Debt / equity | — |
| Current ratio | 0.79 | Free cash flow | -$29.67M | Analyst recommendation | none | Mean target | $7.25 |
| 52w high | $10.99 | 52w low | $0.60 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $33.4M | $35.1M | $34.1M | $44.0M | $37.9M |
| Op margin | -67.4% | -76.3% | -52.4% | -34.6% | -64.3% |
| Net income | -$67.0M | -$22.4M | -$102M | -$33.1M | -$37.3M |
| Gross margin | 96.8% | 96.2% | 95.6% | 95.2% | 97.2% |
| Gross profit | $32.3M | $33.7M | $32.6M | $41.9M | $36.9M |
| Operating income | -$22.5M | -$26.8M | -$17.8M | -$15.2M | -$24.4M |
- Revenue -5% vs prior quarter ($33M vs $35M).
- Gross margin 96.8% (was 96.2% prior quarter).
- Operating margin expanded to -67.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $146M | $145M | $146M | $157M | — |
| Op margin | -62.1% | -82.2% | -88.7% | -90.5% | — |
| Net income | -$196M | -$76.4M | -$143M | -$165M | — |
| Gross margin | 95.9% | 95.9% | 96.6% | 96.7% | — |
| Gross profit | $140M | $139M | $141M | $152M | — |
| Operating income | -$90.7M | -$119M | -$130M | -$142M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-09-11 · Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
2026-09-04 · Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates
2026-09-01 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-21 · Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock
2026-08-20 · Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
2026-08-14 · Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary
2026-08-13 · Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...
2026-08-13 · Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-13 · Karyopharm Therapeutics: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patterns